Sinotherapeutics, Inc. Class ASSE: 688247

"SINOTHERAPEUTICS INC."Announcement on Voluntary Disclosure of Doxofylline Tablets Passing the Consistency Evaluation of Generic Drugs and the Addition of a New Specification

Jul 14, 2026 · Issued by Sinotherapeutics, Inc. Class A via Shanghai Stock Exchange

Announcement on Voluntary Disclosure of Doxofylline Tablets Passing the Consistency Evaluation of Generic Drugs and the Addition of a New Specification

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Sinotherapeutics, Inc. Class A

"SINOTHERAPEUTICS INC."Announcement on Abnormal Fluctuations in Stock TradingJul 3
Announcement on Implementation of Dividend Distribution for 2025Jun 22
Announcement on the Expiry of Planned Time for Shareholders with Over 5% Shares to Reduce Shares and Results of Shareholding ReductionJun 11
Senior Management Member" -- Announcement on Completing Term Change and Election of the Board of Directors and Appointing Senior Management Members and Securities Affairs Representative, as well as Departure of Core Technical PersonnelMay 29

All Sinotherapeutics, Inc. Class A news releases